Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE. Issue 5 (October 2017)

• Record Type: Journal Article
• Authors: Rogiers, Aljosja; Vander Borght, Sara; Tuand, Krizia; Wolter, Pascal; Stas, Marguerite; Boecxstaens, Veerle; Garmyn, Marjan; van den Oord, Joost J.; Vandenberghe, Peter; Bechter, Oliver
• Is Part Of: Melanoma research. Volume 27:Issue 5(2017)
• Publication Date: 2017-10
• Subjects: BRAF inhibitor -- BRAF mutation -- dabrafenib -- MEK inhibitor -- melanoma -- targeted therapy -- trametinib; Melanoma -- Periodicals; Melanoma -- Periodicals; Melanomen; 616.99477
• DOI: 10.1097/CMR.0000000000000376
• Languages: English
• ISSNs: 0960-8931

Abstract

Abstract : Concurrent BRAF-MEK inhibition improves clinical outcomes in patients with advanced BRAF V600E/K-mutant melanoma. There is currently less evidence for the efficacy of this treatment in patients with rare BRAF non-V600E/K genotypes. We report on two patients with rare BRAF exon 15 mutations – BRAF A598_T599insV and V600_K601delinsE – obtaining clinical benefit and a radiological response to inhibitors directed against the mitogen-activated protein kinase pathway. This highlights the importance of using tests that detect both V600E/K and non-V600E/K BRAF mutations to keep open the possibility of treatment with targeted therapy in patients with uncommon, yet potentially actionable, BRAF exon 15 mutations.